A Population Pharmacokinetic Model of Macitentan and Its Active Metabolite Aprocitentan in Healthy Volunteers and Patients with Pulmonary Arterial Hypertension.
Roberta BartolucciAnne-Gaëlle DosneDénes CsonkaJuan José Pérez-RuixoPaolo MagniItalo PoggesiPublished in: Clinical pharmacokinetics (2021)
The comprehensive population pharmacokinetic model adequately described the pharmacokinetics of macitentan and aprocitentan across different dose concentrations, regimens, and formulations. Several covariates significantly influenced the pharmacokinetics of macitentan and aprocitentan, but none was considered clinically relevant.